Search

everythinglearnresearchcommunity

for

Search:↓

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

Androgen receptor overexpression can increase prostate cancer cell growth even without hormones.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

Precise objectives can improve student achievement in health education.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.

CEC levels may be a useful marker for predicting prostate cancer progression.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Researchers found four natural compounds that can change DHT levels in prostate cancer cells.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Green tea extract and cycling hormone treatments may help treat advanced prostate cancer.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Minoxidil can reduce functions related to androgen receptors.

Analog 23 is a promising compound for prostate cancer treatment.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

ERG increases SOX9, promoting prostate cancer growth and invasion.